

Here for you

Pharmacy and Therapeutics Committee Meeting

Agenda

Wednesday, October 18, 2023

7:30 - 9:30 am

San Francisco Health Plan 50 Beale St. San Francisco, CA, 94105 City Hall Conference Room Microsoft Teams meeting

Join on your computer, mobile app or room device

Click here to join the meeting
Meeting ID: 265 745 962 419
Passcode: wGQZQq
Or call in (audio only)
+1 323-475-1528,,829249014#
United States, Los Angeles
Phone Conference ID: 829 249 014#

To arrange for public building access, please contact Luke Nelson at 415-615-4269

- 1) Call to order non-voting item (est. time 2 minutes)
 - Kaitlin Hawkins, PharmD, Pharmacy Operations Manager, San Francisco Health Plan
 - Conflict of interest check
 - Attendance/Quorum
 - Agenda overview
- 2) Senior Medical Director Introduction & Informational Updates non-voting item (est. time 5 minutes) Monique Yohanan, MD, MPH, Senior Medical Director, San Francisco Health Plan
- 3) Review and Approval of July 19, 2023, P&T minutes <u>voting item</u> (est. time 3 minutes) *Kaitlin Hawkins, PharmD, Pharmacy Operations Manager, San Francisco Health Plan*

ADJOURN TO CLOSED SESSION

Kaitlin Hawkins, PharmD, Pharmacy Operations Manager, San Francisco Health Plan

- 4) Consent Calendar **voting item** (est. time 5 minutes)
 - Kaitlin Hawkins, PharmD, Pharmacy Operations Manager, San Francisco Health Plan
 - Drug and Class Reviews
 - o Endocrinology: Somatostatics Class Review
 - o Neurology: DaybueTM (trofinetide) Monograph
 - o Pain: Non-Opioid Medications Class Review
 - o Psychiatry: Attention Deficit Hyperactivity Disorder Class Review
 - Drug Utilization Review (DUR) Reports and/or Educational Items
 - Fraud, Waste and Abuse (FWA) DUR Report: Multiple Providers and Multiple Pharmacies
 2Q2023
 - o FWA: Controlled Substances Report 2Q2023
 - o Antipsychotics Adherence DUR Report
 - Education Materials:
 - Provider Materials: "Recommended Agents for Asthma and COPD on Medi-Cal Rx Contract Drug List and SFHP Healthy Workers HMO Formulary"
 - Provider Materials: "2023 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Report"
 - Magellan Rx Retrospective DUR Quarterly Activities 3Q2023
 - Migraine letter
 - Quarterly Prospective DUR Report 2Q2023



Here for you

Pharmacy and Therapeutics Committee Meeting

Agenda

- 5) Discussion and Recommendations for Changes to SFHP Formulary and Prior Authorization Criteria and Drug Utilization Review Reports for Select Drug Classes <u>voting item</u> (est. time 70 mins)

 Kaitlin Hawkins, PharmD, Pharmacy Operations Manager, San Francisco Health Plan

 Eileen Kim, PharmD, Clinical Pharmacist, San Francisco Health Plan

 Jessica Shost, PharmD, Clinical Pharmacist, San Francisco Health Plan
 - Cardiology
 - o Anticoagulants Class Review
 - o Heart Failure, Angina & Coronary Artery Disease Class Review
 - Neurology
 - Sleep Disorders (Narcolepsy) Class Review
 - Skyclarys (omaveloxolone) Monograph
 - Ophthalmology
 - o Glaucoma Class Review
 - Otorhinolaryngology
 - o Allergy, Cough, & Cold Medications Abbreviated Review
 - Psychiatry
 - o Antidepressants Class Review
 - o Antidepressants Adherence Drug Utilization Review (DUR) Report
 - o Antidepressants Regimen DUR Report
 - Rheumatology
 - Biologics and Disease Modifying Anti-Rheumatic Drugs (DMARDs) Class Review
- 6) DUR Program Updates, Reports, and/or Educational Items non-voting item (est. time 15 minutes) Jessica Shost, PharmD, Clinical Pharmacist, San Francisco Health Plan
 - High Dose Opioids and Concurrent Central Nervous System Depressants DUR Report

RECONVENE IN OPEN SESSION

Summary of Closed Session – non-voting item (est. time 5 minutes)

Kaitlin Hawkins, PharmD, Pharmacy Operations Manager, San Francisco Health Plan

- 7) Annual Pharmacy Policies and Procedures (P&Ps) Review <u>voting item</u> (est. time 4 minutes) Sue Chan, Pharmacy Compliance Program Manager, San Francisco Health Plan
 - Pharm-02 Pharmacy Prior Authorization
 - Pharm-03 Pharmacy Network Credentialing
 - Pharm-14 Pharmacy Drug Utilization Review Program
- 8) Review and Approval of Prior Authorization Criteria Interim Changes <u>voting item</u> (est. time 3 minutes) Eileen Kim, PharmD, Clinical Pharmacist, San Francisco Health Plan
- 9) Review and Approval of Formulary Interim Changes <u>voting item</u> (est. time 3 minutes) Eileen Kim, PharmD, Clinical Pharmacist, San Francisco Health Plan
- 10) Appendix: Magellan Pipeline Report 3Q2023 non-voting item (est. time 5 minutes) Steve Nolan, PharmD, Pharmacist Account Manager, Magellan Rx Management
- 11) Adjournment
 - Upcoming P&T Committee meeting dates
 - o Wednesday, January 17, 2024
 - o Wednesday, April 17, 2024
 - O Wednesday, July 17, 2024
 - o Wednesday, October 16, 2024